Genetic Technologies Ltd - Company Profile
Powered by 
All the data and insights you need on Genetic Technologies Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Genetic Technologies Ltd Strategy Report
- Understand Genetic Technologies Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Genetic Technologies Ltd (GTG) is a molecular diagnostic company that offers testing products and services to assess sporadic breast cancer risk and colorectal cancer risk assessment. The company delivers the offerings by GeneType for breast cancer tests and GeneType test for colorectal cancer. GeneType for breast cancer, a test that examines woman’s clinical risk factors with scientifically validated genetic biomarkers, to enable personalized breast cancer risk assessment and GeneType for Colorectal Cancer combines patient age, genetic markers and family history to provide more accurate assessment of colorectal cancer risk. The company serves healthcare providers and patients in the US and Australia. GTG is headquartered in Fitzroy, Victoria, Australia.
Headquarters
Australia
Address
60-66 Hanover St, Fitzroy, Melbourne, Victoria, 3065
Website
www.gtglabs.com
Telephone
61 3 94151135
No of Employees
60
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GTG (ASX)
Revenue (2022)
$6.0M
27.8%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-64.8%
(2022 vs 2021)
Market Cap*
$9.9M
Net Profit Margin (2022)
XYZ
-28.9%
(2022 vs 2021)
* As of and is in US$
Products and Services
| Products | Services |
|---|---|
| GeneType for Breast Cancer | Diagnostic Services |
| GeneType for Colorectal Cancer | |
| GeneType for Ovarian Cancer | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In September, the company entered into an agreement with GCPH to establish a precision medicine clinic at the hospital. |
| 2022 | Acquisitions/Mergers/Takeovers | In July, the company acquired the UK-based AffinityDNA. |
| 2022 | Contracts/Agreements | In May, the company entered into an agreement to acquire brand and distribution rights of AffinityDNA. |
Competitor Comparison
| Key Parameters | Genetic Technologies Ltd | Sonic Healthcare Ltd | Syntara Ltd | AusBiotech Ltd | Portland Surgical Products Pty Ltd |
|---|---|---|---|---|---|
| Headquarters | Australia | Australia | Australia | Australia | Australia |
| City | Melbourne | Sydney | Frenchs Forest | Melbourne | Portland |
| State/Province | Victoria | New South Wales | New South Wales | Victoria | Victoria |
| No. of Employees | 60 | 41,000 | 107 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Simon Morriss | Chief Executive Officer | Senior Management | 2021 | - |
| Kathryn Andrews | Chief Financial Officer; Secretary | Senior Management | 2024 | - |
| Richard Allman | Chief Scientific Officer | Senior Management | - | - |
| Carl Stubbings | Chief Commercial Officer | Senior Management | - | - |
| Peter Rubinstein | Chairman | Non Executive Board | 2020 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer